Repoxegen Therapeutics

Repoxegen Therapeutics is developing an oral small molecule inhibitor of soluble epoxide hydrolase, a key enzyme in fatty acid metabolism implicated in neuro-inflammation and retinal degeneration. Their lead compound has demonstrated efficacy in animal models of diabetic retinopathy, with a favorable safety profile and readiness for IND-enabling studies. The company aims to address significant unmet needs in nonproliferative diabetic retinopathy with a disease-modifying oral therapy that avoids the need for intraocular injections. Human clinical data from earlier generation inhibitors support the safety of this approach[1][3][5].